- Conditions
- Fibrostenotic Crohn's Disease
- Interventions
- AGMB-129, Placebo
- Drug
- Lead sponsor
- Agomab Spain S.L.U.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Hamden, Connecticut • Miami, Florida • Orlando, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,030
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Idiopathic Short Stature
- Interventions
- Vosoritide Injection, Human Growth Hormone, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 35
- States / cities
- California City, California • Los Angeles, California • Oakland, California + 28 more
- Conditions
- ANCA-associated Vasculitis
- Interventions
- CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Nicotine Dependence, Contraception
- Interventions
- Low-dose Progesterone, High-dose Progesterone
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- HIV Infections
- Interventions
- PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV)
- Biological
- Lead sponsor
- International AIDS Vaccine Initiative
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Overweight
- Interventions
- NNC0174-0833, Semaglutide, Placebo (NNC0174-0833)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Allergic Conjunctivitis
- Interventions
- CsA high dose, CsA low dose, PA, Placebo
- Drug
- Lead sponsor
- Fovea Pharmaceuticals SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Dermatitis, Atopic
- Interventions
- MK-6194, Placebo
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Placebo, RG7774
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more
- Conditions
- Primary Open-angle Glaucoma (POAG), Ocular Hypertension
- Interventions
- SHP639 (n=60), Placebo Comparator (n=24)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Migraine
- Interventions
- Ubrogepant, Placebo-Matching Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 1,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 125
- States / cities
- Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- ADZENYS XR-ODT, Placebo Oral Tablet
- Drug
- Lead sponsor
- Aytu BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Herpes Simplex
- Interventions
- Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Rochester, New York
- Conditions
- Sleep Apnea
- Interventions
- Danavorexton, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • La Jolla, California + 14 more
- Conditions
- Dry Eye Disease
- Interventions
- OK-101, Placebo
- Drug
- Lead sponsor
- Okyo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
- Conditions
- Microbiome, Immune Function, Inflammation
- Interventions
- Placebo, Prebiotic supplement
- Dietary Supplement
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hyperlipidemias
- Interventions
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos
- Combination Product · Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more
- Conditions
- Healthy
- Interventions
- Lysergic Acid Diethylamide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Heart Failure
- Interventions
- AZD5462, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- Alexander City, Alabama • Northridge, California • Torrance, California + 11 more
- Conditions
- Schizophrenia
- Interventions
- Lurasidone, Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Cerritos, California • Escondido, California + 22 more
- Conditions
- Alzheimer Disease
- Interventions
- Bumetanide, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- CBX129801
- Drug
- Lead sponsor
- Cebix Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 22
- States / cities
- Escondido, California • Fresno, California • Irvine, California + 18 more
- Conditions
- Charcot-Marie-Tooth Disease, Type Ia
- Interventions
- Ascorbic acid (Vitamin C), placebo
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 13 Years to 70 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Rochester, New York
- Conditions
- Alzheimer Disease
- Interventions
- Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut